Myeloma News

A triplet regimen extended OS compared with the current standard of care for patients with relapsed or refractory multiple myeloma, according to a topline data announcement.

Inherited variants in DNA repair genes such as BRCA1 and BRCA2 may increase risk for multiple myeloma, according to results of a retrospective study.

Disparities in hematopoietic stem cell transplantation utilization for blood cancers have narrowed over time but still persist, according to study results.

Decreasing the amount of dexamethasone that individuals with newly diagnosed multiple myeloma received did not affect survival, according to a secondary analysis of completed clinical trials.

The addition of daratumumab to maintenance lenalidomide extended PFS for patients who underwent stem cell transplant for newly diagnosed multiple myeloma, according to study results.

Multiple studies published since this summer suggest chimeric antigen receptor T-cell therapies are comparably effective in real-world settings as they have been in pivotal clinical trials.

A simple blood test that measures lymphocyte count may accurately predict response to chimeric antigen receptor T-cell therapy among patients with relapsed multiple myeloma, according to study results.

In this video, Nisha Joseph, MD, an associate professor in the Department of Hematology and Medical Oncology at Emory University School of Medicine, discusses how she approaches putting together a treatment plan for a patient with multiple myeloma.